TRANSFORMING MEDICINE. RESTORING WELLBEING.
DURECT is leveraging its epigenetic regulator program and proprietary drug delivery technologies to develop novel and lifesaving therapies for a wide range of diseases with few current treatment options.
DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program.
INVESTOR RELATIONS >
DURECT's Investor section provides comprehensive information to existing and potential stockholders, including up-to-date stock information, financial reports, investor events and more.
PIPELINE : PHASE 2
DUR-928
The first endogenous epigenetic regulator clinically tested for the treatment of acute organ injury and chronic liver diseases.
News
June 9, 2021
DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs
May 4, 2021
April 27, 2021
VIEW ALL >
BUSINESS DEVELOPMENT | CAREERS | CONTACT | LEGAL NOTICE | PRIVACY POLICY
DURECT manufactures ALZET® osmotic pumps.